Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China.

Dai, Hongbin; Wang, Wenyue; Fan, Xin; Chen, Yongfa

Dai, Hongbin; Wang, Wenyue; Fan, Xin; Chen, Yongfa.

Afiliación

Dai H; School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Wang W; School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Fan X; School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Chen Y; School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.

Front Med (Lausanne) ; 10: 1122731, 2023.

Article en En | MEDLINE | ID: mdl-36865055

Palabras clave

China; camrelizumab; cost-effectiveness; non-small cell lung cancer; partitioned survival analysis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Front Med (Lausanne) Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google